NASDAQ:CYAD Celyad Oncology (CYAD) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free CYAD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.40▼$0.6550-Day Range$0.59▼$0.8552-Week Range$0.46▼$3.07Volume3,009 shsAverage VolumeN/AMarket Capitalization$15.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesSocial MediaStock AnalysisHeadlinesSocial Media Get Celyad Oncology alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Celyad Oncology Stock (NASDAQ:CYAD)Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Read More Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! CYAD Stock News HeadlinesApril 4, 2024 | finance.yahoo.comCelyad Oncology Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 29, 2024 | seekingalpha.comCSBR Champions Oncology, Inc.April 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”January 17, 2024 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlookJanuary 16, 2024 | finance.yahoo.comCelyad Oncology provides fourth quarter 2023 business update and 2024 outlookDecember 17, 2023 | businesswire.comCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)December 4, 2023 | finance.yahoo.comCelyad Announces Management ChangeNovember 14, 2023 | tmcnet.comInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 MayApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.November 11, 2023 | lse.co.ukCelyad Oncology Share Price (CYAD.BR)November 9, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology reports third quarter 2023 financial results and recent business highlightsNovember 9, 2023 | finance.yahoo.comCelyad Oncology reports third quarter 2023 financial results and recent business highlightsSeptember 26, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology announces the termination of its American Depository Receipt programSeptember 25, 2023 | marketwatch.comCelyad Oncology to Terminate ADR ProgramSeptember 25, 2023 | finance.yahoo.comCelyad Oncology announces the termination of its American Depository Receipt programSeptember 15, 2023 | finance.yahoo.comCelyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLCSeptember 12, 2023 | businesswire.comCelyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SASeptember 12, 2023 | ca.finance.yahoo.comCelyad Oncology SA (CYAD.BR)September 7, 2023 | finance.yahoo.comCelyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLCSeptember 4, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology Reports First Half 2023 Financial Results and Recent Business HighlightsSeptember 4, 2023 | finance.yahoo.comCelyad Oncology Reports First Half 2023 Financial Results and Recent Business HighlightsSeptember 4, 2023 | investing.comCelyad Oncology (CYADY) Earnings Dates & ReportsAugust 29, 2023 | finance.yahoo.comCelyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical ShareholdersAugust 25, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholdersJuly 19, 2023 | investing.comCelyad Oncology SA (CYADY)May 16, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology announces receipt of Nasdaq delisting noticeMay 15, 2023 | finance.yahoo.comCelyad Oncology Announces Receipt of Nasdaq Delisting NoticeSee More Headlines Receive CYAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYAD CUSIPN/A CIK1637890 Webwww.celyad.com Phone(210) 039-4100Fax321-039-4141Employees95Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales144.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.00Miscellaneous Outstanding Shares26,520,000Free Float26,276,000Market Cap$15.91 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesGeorges RawadiChief Executive Officer & Executive DirectorDavid GeorgesVice President-Finance & AdministrationEytan BremanDirector-Research & DevelopmentAn PhanHead-LegalKey CompetitorsOrgenesisNASDAQ:ORGSPieris PharmaceuticalsNASDAQ:PIRSAytu BioPharmaNASDAQ:AYTUAvalo TherapeuticsNASDAQ:AVTXNeuroBo PharmaceuticalsNASDAQ:NRBOView All Competitors CYAD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Celyad Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX). When did Celyad Oncology IPO? Celyad Oncology (CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. This page (NASDAQ:CYAD) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celyad Oncology SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
